Premium
International study on low‐grade primary central nervous system lymphoma
Author(s) -
Jahnke Kristoph,
Korfel Agnieszka,
O'Neill Brian Patrick,
Blay JeanYves,
Abrey Lauren E.,
Martus Peter,
Poortmans Philip M. P.,
Shenkier Tamara N.,
Batchelor Tracy T.,
Neuwelt Edward A.,
Raizer Jeffrey J.,
Schiff David,
Pels Hendrik,
Herrlinger Ulrich,
Stein Harald,
Thiel Eckhard
Publication year - 2006
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.20804
Subject(s) - medicine , primary central nervous system lymphoma , radiation therapy , central nervous system , chemotherapy , lymphoma , central nervous system disease , retrospective cohort study , disease , pathological , surgery
Objective The aim of this study was to characterize the clinical presentation, course, and outcome of low‐grade primary central nervous system lymphoma. Methods Cases were assessed in a retrospective series collected from 18 cancer centers in 5 countries. Results Forty patients (18 men, 22 women; median age, 60 years [range, 19–78]) were identified. Involvement of a cerebral hemisphere or deeper brain structures was seen in 37 patients, only leptomeningeal involvement in 2 patients, and spinal cord disease in 1 patient. Chemotherapy/radiotherapy was conducted in 15 patients, radiotherapy alone in 12, chemotherapy alone in 10, and tumor resection alone in 2, whereas 1 patient received no treatment. The median progression‐free, disease‐specific, and overall survival were 61.5 (range, 0–204), 130 (range, 1–204), and 79 (range, 1–204) months, respectively. Only age 60 years or older was associated with shorter progression‐free ( p = 0.009), disease‐specific ( p = 0.015), and overall survival ( p = 0.001) in multivariate analysis. Interpretation Low‐grade primary central nervous system lymphoma differs from the high‐grade subtype in its pathological, clinical, and radiological features. It has a better long‐term outcome than primary central nervous system lymphoma in general with age 60 years or older adversely affecting survival. Ann Neurol 2006